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Abstract 
The clinical decision to control risk factors for cardiovascular disease (CVD) in the elderly takes the followings into consideration: (1) 
the elderly life expectancy; (2) the elderly biological age and functional capacity; (3) the role of cardiovascular disease in the elderly group; 
(4) the prevalence of risk factors in the elderly; and (5) The effectiveness of treatment of risk factors in the elderly. A large number of studies 
showed the efficacy of secondary and primary prevention of dyslipidemia in the elderly. However, the only trial that included patients over 
80 years was the Heart Protection Study (HPS). Statins are considered the first line therapy for lowering low-density lipoprotein cholesterol 
(LDL-C). Because lifestyle changes are very difficult to achieve, doctors in general tend to prescribe many drugs to control cardiovascular 
risk factors. However, healthy food consumption remains a cornerstone in primary and secondary cardiovascular prevention and should be 
implemented by everyone.  
J Geriatr Cardiol 2012; 9: 83−90. doi: 10.3724/SP.J.1263.2011.12292 
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1  Introduction  
Until recently, a discussion of risk factors and prevention 
of atherosclerosis would be considered unprecedent, since 
atherosclerosis was considered a natural aging process. The 
control of risk factors was supposed to have less or little 
importance in the elderly and it was questioned if it were 
really needed in the octogenarians and beyond. 
Nevertheless, this concept was gradually changed by the 
inclusion of the elderly in clinical studies, a small number in 
the beginning and progressively a larger number. Besides 
verifying the important distinction between relative risk and 
absolute risk which had a greater value when applied to the 
elderly, it was observed that although the relative risk of 
cardiovascular disease associated with any risk factor decreased 
with aging, the absolute risk was markedly increased in the 
elderly. 
The term “elderly” accounts for three distinct aging 
groups: the young elderly (from 65–74 years-old) the old-old 
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(from 75–79 years old) and octogenarians and beyond. The 
heterogeneity, usual within any age group, is more prevalent 
among the octogenarians and beyond group composed of 
very old, lucid, and independent patients with an active 
lifestyle, but also stroke patients depending on caregivers, or 
with Alzheimer’s, and experiencing poor quality of life. 
The clinical decision to control risk factors for cardio-
vascular disease (CVD) in the elderly takes into consi-
deration five topics. 
1.1 The elderly life expectancy 
The elderly life expectancy in Brazil according to the 
2005 national census, and a theoretical projection evaluating 
the life expectancy of the oldest made in 2008 are listed in 
Table 1.[1,2] 
According to US NHANES III,[3] the treatment of a risk 
factor, for instance, the dyslipidemia, is not indicated if the 
life expectancy is inferior to 2 years. This was not the case 
in any of the age group above.  
1.2 The elderly biological age and functional capacity 
The elderly biological age and functional capacity will 
guide the treatment more effectively than only the chrono-
logical age. The biological age is affected by the presence of 
co-morbidities, such as severe pulmonary disease, vascular  
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Table 1. Life expectancy of the elderly in Brazil.[1] 
 
Age (year) Life Expectancy (year) 
65 17.40 
66 16.70 
67 16.10 
68 15.50 
69 14.90 
70 14.30 
71 13.70 
72 13.10 
73 12.60 
74 12.10 
75 11.60 
76 11.10 
77 10.60 
78 10.20 
79 9.70 
80 9.30 
Theoretical projection[2]  
85  7.64  
90  6.16  
95  5.02  
100  4.14  
 
disease, anemia, renal insufficiency, thyroid disease, diabetes, 
cognitive dysfunction, pulmonary hypertension, depression, 
and so on. These co-morbidities will affect the dosage and 
the choice of treatment. The functional capacity can be 
affected by stroke, dementia, fragility, or severe osteoporosis 
and will have a profound impact on the decision of treatment. 
1.3 The role of cardiovascular disease in the elderly 
group 
Cardiovascular disease is a major threat to the health of 
older people. Elderly population accounting for more than 
75% of total coronary heart disease (CHD) mortality and 
well over 50% of all acute myocardial infarctions (MI) in 
the United States.[4] Risk reduction in people older than 65 
years is essential because two-thirds to three-quarters of 
them have either clinical CHD or subclinical atherosclerosis.[5] 
According to van Oostrom et al,[6] the morphology of 
atherosclerotic plaques in patients with carotid artery 
stenosis changes predisposes them, with increasing age, to 
more instability with an increased chance of clinical events. 
1.4 The prevalence of risk factors in the elderly 
According to the “Estudo Multicêntrico em Idosos” 
(Multicenter study in the elderly or EMI study),[7] the 
prevalence of sedentary lifestyle in the Brazilian elderly is 
74%, hypertension 53%, dyslipidemia 33%, obesity 30%, 
diabetes 13% and smoking 6%. Dyslipidemia is prevalent 
even in those at an advanced age. Despite this high prevalence 
and the frequent occurrence of CHD, there is a strong bias 
in the prevention and treatment of cardiovascular disease 
due to the poor assessment and treatment of lipid disorders 
through primary and secondary prevention in the elderly.[4] 
1.5 The effectiveness of management of risk factors in 
the elderly 
There is currently overwhelming evidence that the 
treatment of elderly dyslipidemia is effective in the reduction 
of CVD in the elderly. For instance, meta-analysis of 26 
published interventional studies of the last Cholesterol 
Treatment Trialists Collaboration,[8] showed the reduction of 
about 25% in the occurrence of a first major vascular event 
due to a 1 mmol/L (38.6 mg/dL) decrease in low-density 
lipoprotein cholesterol (LDL-C), with benefits experienced 
in every age range.[8] In a previous review of the treatment 
of dyslipidemia in the elderly, Shao et al.[9] pointed out the 
benefit of treatment of dyslipidemia in the elderly might be 
evident as early as the first two years of treatment. 
2 Clinical evidence of the efficacy of the 
pharmacological treatment of dyslipidemia in 
the elderly 
2.1 Secondary prevention 
The 2010 “II Brazilian Guidelines of Geriatric Cardiology 
from the Brazilian Society of Cardiology” (Table 2) pointed 
out studies with expressive numbers of elderly.[10] They 
reported the efficacy of secondary and primary prevention 
of elderly dyslipidemia treatment with statins, considered as 
first line therapy for lowering LDL-C. There are also studies 
with fibrates as well, with their major effect on triglycerides 
and high-density lipoprotein cholesterol (HDL-C). These 
studies showed the following: 
(1) Reductions of relative risk for mortality from all 
causes and cardiovascular mortality with statins in the elderly 
were equal or higher than those observed in the younger 
patients (Scandinavian Simvastatin Survival Study[11] (4S): 
4,444 patients with coronary artery disease with 1021 within 
the age range 65 to 70 years old). 
(2) Higher reductions of coronary death, non-fatal MI 
angioplasty or surgery in the elderly (with the use of statins) 
than in the non-elderly: Cholesterol and Recurrent Events 
(CARE) Study[12] in older patients (1283 elderly from 65 to 
75 years of a total of 4159 post-infarction patients with discrete 
elevated levels of total cholesterol (TC) and LDL-C). 
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Table 2.  II Brazilian guidelines of geriatric cardiology recom-
mendations.[10] 
 
LDL-C goal in elderly patient with 1 risk factor: < 130 mg/dL 
Level of LDL for change of life style with optional pharmacological 
treatment: 130−159 mg/dL. 
Level of LDL for change of life style and pharmacological treatment 
≥ 160 mg/dL. 
LDL-C goal in high risk elderly: < 100 mg/dL (High risk elderly are 
identified by the presence of several risk factors) 
Level of LDL-C in order to prescribe change of life style and 
pharmacological treatment: ≥ 100 mg/dL. 
LDL-C goal in the very high risk elderly < 70 mg/dL  
Very high risk factor elderly are identified by the presence of CAD in 
the presence of one or more risk factors of difficult correction as 
diabetes or smoking, or with ACS. 
Goal of LDL-C requiring change of life style with optional pharmaco-
logical treatment 70–99 mg/dL 
Goal of LDL-C requiring change of life style and pharmacological 
treatment: ≥ 100 mg/dL. 
Recommendations 
I: level of evidence A 
Diet and physical activity for the treatment of dyslipidemia. 
Statin in high LDL for secondary and primary prevention. 
IIa: level of evidence C  
Physical activity and niacin in low HDL-C isolated. 
 
CAD: coronary artery disease; HDL-C: high-density lipoprotein cholesterol; 
LDL-C: low-density lipoprotein cholesterol;. 
  
(3) Reductions of 22% of deaths for coronary artery 
disease (CAD) or non-fatal MI and 59% of transitory stroke 
with gemfibrozil-(Veterans Affairs HDL-C Intervention Trial 
(VA-HIT)[13]: 50% of the participants were 65–74 years of 
age). There is no clinical trial with fibrate in patients over 75 
years old. 
(4) Reductions of mortality, incidence of first MI and 
stroke in all age groups, including octogenarians and 
beyond, with statins in primary and secondary prevention 
(Heart Protection Study (HPS)[14]: 20,536 patients from 
40–80 years of age with 5806 patients ≥ 70 years. It was the 
first study to show that patients prescribed statins with 
relatively low levels of cholesterol had similar benefits to 
cohorts with higher cholesterol levels). 
(5) Reductions of mortality and composed end-point 
(mortality, MI, and stroke) in secondary and primary prevention 
study in the Prospective Study of Pravastatin in the Elderly 
at Risk (PROSPER)[15]: It was performed exclusively in 
elderly patients: 5804 participants from 70–82 years, with 
vascular disease (coronary, cerebral, peripheral) or risk 
factors (hypertension, smoking, diabetes) without established 
CVD.  
(6) Higher reductions of clinical events with higher 
reductions of LDL-C (Pravastatin or atorvastatin evaluation 
and infection therapy-thrombolysin myocardial infarction 
22 (PROVE-IT-TIMI 22)[16]: a study with 4,162 patients 
with acute coronary syndrome, 30% with age ≥ 65 years, 
was performed in order to evaluate if a reduction of LDL-C 
levels to 70 mg/dL with atorvastatin 80 mg was most effective 
in reducing events than the standard level of LDL-C (100 
mg/dL) obtained with pravastatin 40 mg.  
(7) The reduction of LDL-C to 70 mg/dL in acute 
coronary syndrome (ACS) had similar beneficial effects in 
patients ≥ 70 years as well as in younger patients, according 
to the analysis of elderly sub-group (Pravastatin or atorva-
statin evaluation and infection therapy-thrombolysin myo-
cardial infarction 22 (PROVE-IT-TIMI 22)[17]: 3150 patients 
≤ 70 years vs. 634 patients with ≥ 70 years). 
(8) Reductions of 22% of major cardiovascular events 
with the use of statins at 80 mg/d compared to 10 mg/d. The 
study included 10,001 patients with stable CAD, 37% with 
age ≥ 65 years, to evaluate cardiovascular risk effects on 
reduction of LDL-C to levels below the recommended by 
guidelines. No differences were observed in total mortality 
(Treating To New Targets (TNT)[18]: Atorvastatin 10 mg vs. 
Atorvastatin 80 mg).  
(9) Significant reductions of mortality and trends to less 
acute events in a study that included only elderly: 893 elderly 
patients from 65 to 85 years, stable CAD and ischemia in a 
48 hours Holter with a higher doses of statin (Atorvastatin 
80 mg vs. Pravastatin 40 mg): Study Assessing Goals in the 
Elderly (SAGE).[19] 
(10) Reductions of 44% of composed end-points, 55% of 
non-fatal MI, 48% of non-fatal stroke and 20% of mortality 
with statins. (JUPITER trial: 17,802 male > 55 years and 
women > 65 years, without established cardiovascular 
disease, with LDL-C < 130 mg/dL and C-reactive protein ≥ 
2 mg/L).[20] 
The National Cholesterol Education Program III (NCEP III)[21] 
presented an optional, more aggressive, desirable level of 
LDL-C at < 70 mg/dL in very high risk patients, with the 
goal of 100 mg/dL for the ones with high risk.  
It is worthy to note that these clinical trials included 
patients both from the young elderly group (65–74 years old) 
and from the old-old group (75–79 years old). The only trial 
that included patients over 80 years was the HPS. Unfor-
tunately, there is no information about the number of 
octogenarians included in the HPS. Also, there is no data 
regarding their ages at the end of the study and whether any 
reached the mean five year follow-up end-point that will 
provide us with information about 85 year old patients. 
Based on this, for the moment, it is possible to acknow-
ledge the benefits of statin therapy in the elderly from 65 to 
80, and perhaps 85 year old elderly with established CVD. 
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The absolute risk reduction was as effective as in other age 
groups with the drug well tolerated by them.  
For the oldest old group, the biological age and functional 
capacity will guide the choice of treatment. 
2.2 Primary prevention 
In the elderly without established CAD, but with risk 
factors for CAD, drug treatment should be introduced when 
indicated by the high prevalence of subclinical disease. This 
recommendation is supported by the studies: Cardiovascular 
Health Study (CHS),[22] PROSPER,[14] and HPS.[13] The 
National Cholesterol Education Program III (NCEP III)[23] 
also recommends dyslipidemia treatment in elderly patients 
without CAD, since the studies above mentioned certify the 
efficacy of statin therapy in CAD high risk elderly, even 
without diagnosed disease. 
Since 1989, CHS followed 5,888 healthy elderly ≥ 65 
years. In order to evaluate statin use in primary prevention, 
2,914 elderly without CVD were followed for seven years. 
At the end of the study, a 56% reduction of the incidence of 
cardiovascular events and a 44% reduction in mortality 
from all causes in the 65–73 year old participants and in the 
≥ 74 years was observed. Pharmacological therapy in 
primary prevention should be considered in high risk elderly 
with diabetes, several risk factors, or subclinical disease. 
Again, the evidence for primary prevention is consistent 
for the young old and old-old group. As mentioned previously, 
the only trial that included the oldest-old group of patients 
over 80 years in secondary and primary prevention was the 
HPS.  
Based on this, for the moment, it is possible to recognize 
the benefits obtained with the statins among the elderly 
from 65 to 80 years of age, and possibly elderly 85 years old 
with established CVD. The absolute risk reduction was as 
effective as in the other age group and the drug was well 
tolerated by them. There are no large trials on the use of 
fibrates on lipid reduction or cardiovascular risk reduction 
in patients over 75 years old.[9] 
For the oldest old group regarding primary prevention 
the biological age and functional capacity will guide the 
choice of treatment. 
2.2.1  HDL-C 
The HDL-C is a very important lipid fraction in the 
elderly.[9] Epidemiologic studies show low levels of HDL-C 
have a strong correlation with global risk of atherosclerosis 
and CAD. The results of the Framingham Heart Study 
showed that the cardiovascular risk was more important in 
patients with high HDL-C and low HDL-C, but it remained 
present in patients with relatively low LDL-C and low 
levels of HDL-C.[9,24] A study from the Veterans Admini-
stration demonstrated a strong inverse risk relationship 
between HDL-C and CAD, even in patients with very low 
levels of LDL-C.[9,25] 
Exercises, weight-loss, moderate use of alcohol and use 
of nicotinic acid, fibrate and statins can raise HDL-C levels. 
Niacin or nicotinic acid is considered the best drug to raise 
low HDL-C. Nevertheless, the side effects of flushing of the 
skin make it intolerable for some elderly. This can be 
ameliorated by an initial low dose and gradual increase of 
the drug together with ingestion after meals and no hot 
liquid. Recently, there is the option of niacin linked to 
laropiprant that reduces the chance of flushing occurrence. 
2.2.2  Cholesteryl ester transfer protein (CETP) inhibitor 
A novel class of therapeutic agent in development is the 
CETP inhibitors. They promote the transfer of cholesteryl 
esters from HDL-C to other lipoproteins; the inhibition of this 
protein raises HDL-C levels and decrease LDL-C levels.[26]  
Torcetrapib was the first one of this class. Torcetrapib[27] 
was tested initially in 162 individuals in the age range 18 to 65 
years old with below-average HDL-C levels (men < 44 mg/dL; 
women < 54 mg/dL). It showed a substantial dose-dependent 
elevation in HDL-C, followed by a moderate decrease in 
LDL-C at the higher doses. It was generally well tolerated. 
It was then tested on a first phase 3 CETP inhibitor trial as 
part of a larger clinical trial at the Investigation of Lipid Level 
Management to Understand its Impact in Atherosclerotic 
Events (ILLUMINATE trial[26]). This trial involved 15,067 
patients from 45 to 75 years old (mean age 61 years, 78% 
male, 93% white) with CHD or CHD risk equivalent (type 2 
diabetes). Subjects were randomized to torcetrapib plus 
atorvastatin or to atorvastatin alone. After an average 12 
months of follow-up, the torcetrapib patients showed an increase 
of 72.1% in HDL-C and a decrease of 24.9% in LDL-C, 
compared with baseline. But the drug was also associated with 
an increase of 5.4 mmHg in systolic blood pressure, an 
increase of 25% in cardiovascular events, and an increase of 
almost 60% in all-cause deaths. Torcetrapib was also associated 
with a decrease in serum potassium and increases in serum 
sodium, bicarbonate, and aldosterone. Post hoc analyses showed 
an increased risk of death in torcetrapibtreated patients whose 
reduction in potassium or increase in bicarbonate was greater 
than the median change. Further analyses on the causes of 
death showed more fatal stroke with torcetrapib (6 vs. 0), 
more deaths due to cancer (24 vs. 14) and infection (9 vs. 0). 
The drug trial was suspended by the pharmaceutical company. 
Further investigations suggested that the adverse effects 
of torcetrapib were not necessarily related to the inhibition 
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of CETP[28–31] and are not necessarily shared by the others 
members of the class of CETP inhibitors.[28] 
Other new CETP drugs were then tested, including ana-
cetrapib and dalcetrapib. 
 Anacetrapib was tested under the DEFINE trial (The 
Determining the efficacy and tolerability of CETP inhibition 
with Anacetrapib study[28]). It was a randomized, double-blind, 
placebo-controlled trial. The aim was to assess the efficacy 
and safety profile of anacetrapib in patients with CHD or at 
high risk for CHD. It was tested on 1623 patients between 18 
and 80 years of age with LDL-C levels between 50 mg/dL 
and 100 mg/dL (1.3 mmol/L and 2.6 mmol/L) while taking 
statin, an HDL-C level of less than 60 mg/dL (1.6 mmol/L) 
and a triglyceride level of 400 mg/dL (4.5 mmol/L) or less. 
The mean age was 62.5 ± 8.7 years of the anacetrapib group 
and 62.9 ± 9.0 years of the placebo group. They were assigned to 
receive anacetrapib or placebo daily for 18 months. The 
primary end-points were the change in LDL-C (HDL-C level 
was a secondary end point) and safety of the drug. The 
authors concluded that treatment with anacetrapib had robust 
effects on LDL-C and HDL-C levels and, within the limits of 
the power of the study and did not resulted in the adverse 
effects observed with torcetrapib, and more recently 
evacetrapib. 
Dalcetrapib was tested under two phase 2b trials, dal- 
PLAQUE and dal-VESSEL. The purpose of these two studies 
was to assess the safety and efficacy of dalcetrapib with 
different imaging modalities.[32] In the dal-PLAQUE trial, 
dalcetrapib showed no evidence of plaque progression or 
pro-inflammatory properties at 24 months, suggesting a 
favorable safety profile. The dal-VESSEL trial revealed that 
administration of dalcetrapib does not cause endothelial 
dysfunction, or has an effect on ABPM. Nevertheless, the 
confirmation of the long term safety and clinical efficacy of 
dalcetrapib on cardiovascular outcomes must be still stablished. 
This will be provided by the results of the dal-OUTCOMES 
trial, which is still ongoing triglyceridemia. High levels of 
triglycerides have been related to the risk of CAD, but they 
lose significance when adjusted to other variables like 
glycemia and HDL.[9] Nevertheless, even after adjusting for 
HDL-C, the composed hyperlipidemia (i.e., elevated levels 
of LDL-C and triglycerides) is related to the risk of CAD in 
a higher proportion than higher individual levels of LDL-C 
or triglycerides.[9]  
Hypertriglyceridemia treatment should include diet, exercise, 
and nutritional re-education programs.[9] The recommended 
triglycerides level is ≤ 150 mg/dL. When drug use is 
necessary, nicotinic acid is the first line drug due to its 
beneficial effect on LDL-C, HDL-C and triglycerides, 
despite the higher incidence of adverse effects than the other 
dyslipidemia’s drugs. The inhibitors (statins) of hydroxyl-
methylglutaryl CoA reductase are the next choice for their 
efficacy in the reduction of LDL-C, although they have 
modest effects on triglycerides and HDL-C. A higher dose 
of statin seems to significantly decrease triglycerides. 
Statins can be the first treatment choice in those patients 
with very high levels of LDL-C. The fibrates have variable 
effects on LDL-C levels and probably should be used only if 
the fasting levels of triglycerides are ≥ 400 mg/dL to 500 
mg/dL. Finally, when the goal of LDL-C levels is attained, 
but the triglyceride levels remain high with low HDL, the 
use of fibrates in combination with statin can be effective. 
Gemfibrozil should not be used in association with statin 
due to its adverse effects. 
3 Non-pharmacological treatment of dyslipi-
demia 
Because lifestyle changes are very difficult to achieve, 
doctors in general, are prone to prescribe many drugs to 
control cardiovascular risk factors. However, it is very 
important to remember that healthy food consumption remains 
a cornerstone in primary and secondary cardiovascular pre-
vention and should be implemented by everyone. 
3.1 Diet 
One of the most important aspects of human life related 
to atherogenesis is the dietary pattern. Over the years, an 
exhaustive pool of evidence have been accumulating that 
many food items are related positively or negatively with 
the prevalence of atherosclerosis and its complications. 
Nutrients are linked to many atherosclerosis risk factors: 
hypertension, alteration of the lipid profile, obesity, diabetes, 
altered coagulation and probably others still not totally 
understood.  
Diet is a multi-component mixture of many nutrients 
which may interact with one another. We still do not have a 
definitive study of the impact of nutrients on cardiovascular 
disease. Many problems exist in the design of the studies, 
the population being studied is quite often heterogeneous as 
is the diet, and it is the diet that is used as the baseline for 
interventions. Many approaches have been used to examine 
the influence of nutrition on atherosclerosis including cross 
population comparisons, nutritional questionnaires admini-
stered to large population groups, and interventional studies. 
Some of these approaches can be very informative about 
individual nutrients. However, metabolic ward studies where 
the nutrients are varied in a specific fashion without changing 
total calories or nutrient balance, are most likely to yield 
relatively definitive answers, aside from the variable being 
studied. However, they are not closely related to the real 
lives of free living peoples.   
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The primary dietary determinants of hypercholestero-
lemia are fats, particularly saturated fats, and dietary cholesterol. 
Unlike dietary fat which is almost completely absorbed in 
the intestinal tract, the absorption of cholesterol is incomplete 
and is regulated at the intestinal epithelium. The evolution 
of our knowledge about the link between hypercholesterolemia 
and atherosclerosis has been recently revised by Steinberg 
in his recent thematic reviews.[33–35] 
3.2 Unsaturated fatty acids  
The action of fatty acids on the lipid profile depends 
mainly of two distinct characteristics: (1) If they have 
double bonds in their carbon chain, and (2) If their isomeric 
formula is cis or trans. 
Saturated fatty acids do not present any double bonds in 
their carbon chains, only single bonds. Their main represen-
tatives in human nutrition are lauric, myristic and palmitic 
acids. They are present in milk and meat, their derivatives 
are in typical Brazilian food, such as palm oil (dende oil) 
and coco-nut fat. The regular consumption of foods containing 
high amounts of saturated fatty acids leads to an increase in 
plasma LDL-C levels accompanied by an increase in 
HDL-C levels. However, the first effect prevails, leading to 
an atherogenic lipid profile. Milk fatty acids, present in 
whole milk and its derivatives, are the worst ones for the 
lipid profile. 
The first step when orientating a prudential diet is to 
reduce the consumption of foods that contain saturated fats. 
There is one exception among the saturated fatty acids. This 
is stearic acid (18 carbons with no double bounds) that does 
not increase LDL-C levels because upon entering the blood 
stream, it is rapidly transformed in oleic acid (18 carbons 
with one double bound) that has a beneficial action on the 
lipid profile.[36] Stearic acid is an important component of 
cocoa butter. With this in mind, dark chocolate (with no 
other kind of fat) can be an option for those people who like 
this delicacy. 
Unsaturated fatty acids fall into several different categories: 
(1) monounsaturated fatty acids, which the main represen-
tative is oleic acid. It has 18 carbons in its molecular chain 
and only one double bound (C18:1) and is present mainly in 
olive and canola oils, dry fruits (walnuts, almonds, hazelnuts, 
cashew-nuts, Brazilian-nuts) and avocado. Its main action 
on the lipid profile is to decrease LDL-C levels with no 
effect on HDL-C levels. When it is used as a substitute for 
saturated fats in the diet, it can compensate the HDL-C 
decrease observed with the reduction of those.[37] It is 
noteworthy to remember that olive oil is one of the important 
components of the Mediterranean Diet which has a protecting 
effect against CHD.[38] (2) Polyunsaturated fatty acids–they 
can be omega 3 or omega 6 according to the first double 
position on the carbon chain.  
The main representative of omega 6 is linoleic acid, 
which is found mainly in plant oils as safflower, corn and 
soy oils. Their action on the lipid profile is to decrease 
LDL-C levels, but they do not counteract the decrease of 
HDL-C observed with the reduction of saturated fatty acids 
consumption. Linoleic acid is an essential fatty acid because 
it is the precursor of arachidonic acid, which in turn is the 
source of leukotrienes and prostanoids. These molecules 
have a variety of effects on the cardiovascular system, some 
beneficial (e.g., prostacyclin) and others not (e.g., thromboxane). 
Since the unsaturated fatty acids (e.g., linoleic acid) present 
in the LDL-C particles are prone to oxidation it can be 
discussed that such moieties enriched in these fatty acids 
would be proatherogenic.[28] However, there is no evidence 
that diets enriched in omega 6 fatty acids promote lipid 
oxidation.  
The Omega 3 fatty acids can derived from fish oil 
(eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) or from some plants and oils (alfa-linolenic acid). 
Data showing a role in cardiovascular prevention are more 
robust for fatty acids derived from fish oil. A high consum-
ption of fish oil can lower plasma triglycerides levels, blood 
pressure, platelet aggregation, and inflammation, and 
increase vascular relaxation.[39] However, the main benefit 
derived from fish oil consumption appears to be in the 
decrease of sudden cardiac deaths due to fatal arrhythmias 
rather than on the underlying atherosclerosis.[40] There is a 
beneficial effect with the use of fish oil supplements after 
MI as shown by the GISSI-Prevenzione group.[41] 
Trans fatty acids, even as unsaturated fatty acids, can 
propitiate bad changes of the lipid profile, worse than the 
saturated ones, leading to an increase in plasma LDL-C 
levels accompanied by a decrease in HDL-C levels and an 
increase of triglycerides. The main representative of this 
class in human nutrition is elaidic acid, which is found in 
vegetable hydrogenated fats present in many margarines, 
biscuits and cookies, sauces and ice creams. Their consum-
ption must be kept as low as possible.  
Only foods coming from animal sources have cholesterol 
with higher concentrations than in sea food, animal viscera,  
6 Conclusion 
Treatment with statins is recommended for elderly patients 
with established cardiovascular disease. Since elderly people 
often have comorbidities and have altered pharmacokinetics, 
it is recommended to begin lipid lowering medication at a low 
dose and then titrate with caution to achieve target lipid 
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levels. Statin therapy may be considered in elderly subjects 
free of cardiovascular disease, particularly in the presence of 
at least another cardiovascular risk factor, besides age. 
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